A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Gantenerumab (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms GRADUATE-2
- Sponsors Chugai Pharmaceutical; Roche
- 30 Jan 2019 According to a Roche media release, data readout from the GRADUATE programme (GRADUATE 1 and 2 studies) is expected in 2022.
- 31 Aug 2018 Biomarkers information updated
- 24 Jul 2018 Planned End Date changed from 20 Jun 2023 to 2 May 2023.